176 related articles for article (PubMed ID: 20038234)
21. Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
Bagadi S; Saikia T; Pany A; Das B
Clin Lab; 2011; 57(7-8):619-23. PubMed ID: 21888027
[TBL] [Abstract][Full Text] [Related]
22. Mutations in ABL kinase domain are associated with inferior progression-free survival.
Sharma P; Mohanty S; Kochupillai V; Kumar L
Leuk Lymphoma; 2010 Jun; 51(6):1072-8. PubMed ID: 20367437
[TBL] [Abstract][Full Text] [Related]
23. Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.
Markose P; Chendamarai E; Balasubramanian P; Velayudhan SR; Srivastava VM; Mathews V; George B; Viswabandya A; Srivastava A; Chandy M
Leuk Lymphoma; 2009 Dec; 50(12):2092-5. PubMed ID: 19925053
[No Abstract] [Full Text] [Related]
24. MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure.
Agrawal M; Hanfstein B; Erben P; Wolf D; Ernst T; Fabarius A; Saussele S; Purkayastha D; Woodman RC; Hofmann WK; Hehlmann R; Hochhaus A; Müller MC
Leukemia; 2014 Jul; 28(7):1478-85. PubMed ID: 24472814
[TBL] [Abstract][Full Text] [Related]
25. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
26. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
27. Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population.
Yahng SA; Jang EJ; Choi SY; Lee SE; Kim SH; Kim DW
Int J Hematol; 2014 Aug; 100(2):132-40. PubMed ID: 24879034
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance.
Chahardouli B; Zaker F; Mousavi SA; Kazemi A; Ostadali M; Nadali F; Rostami S; Alimoghaddam K; Ghavamzade A
Hematology; 2013 May; 18(3):158-62. PubMed ID: 23540562
[TBL] [Abstract][Full Text] [Related]
29. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
30. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
31. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).
Nicolini FE; Corm S; Lê QH; Sorel N; Hayette S; Bories D; Leguay T; Roy L; Giraudier S; Tulliez M; Facon T; Mahon FX; Cayuela JM; Rousselot P; Michallet M; Preudhomme C; Guilhot F; Roche-Lestienne C
Leukemia; 2006 Jun; 20(6):1061-6. PubMed ID: 16642048
[TBL] [Abstract][Full Text] [Related]
32. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
Cortes JE; Kantarjian HM; Goldberg SL; Powell BL; Giles FJ; Wetzler M; Akard L; Burke JM; Kerr R; Saleh M; Salvado A; McDougall K; Albitar M; Radich J;
J Clin Oncol; 2009 Oct; 27(28):4754-9. PubMed ID: 19720924
[TBL] [Abstract][Full Text] [Related]
33. Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.
Breccia M; Cannella L; Stefanizzi C; Latagliata R; Nanni M; Diverio D; Santopietro M; Federico V; Alimena G
Hematol Oncol; 2010 Jun; 28(2):89-92. PubMed ID: 19728398
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.
Nicolini FE; Hayette S; Corm S; Bachy E; Bories D; Tulliez M; Guilhot F; Legros L; Maloisel F; Kiladjian JJ; Mahon FX; Lê QH; Michallet M; Roche-Lestienne C; Preudhomme C
Haematologica; 2007 Sep; 92(9):1238-41. PubMed ID: 17768119
[TBL] [Abstract][Full Text] [Related]
35. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
Al-Ali HK; Heinrich MC; Lange T; Krahl R; Mueller M; Müller C; Niederwieser D; Druker BJ; Deininger MW
Hematol J; 2004; 5(1):55-60. PubMed ID: 14745431
[TBL] [Abstract][Full Text] [Related]
36. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Pfeifer H; Wassmann B; Pavlova A; Wunderle L; Oldenburg J; Binckebanck A; Lange T; Hochhaus A; Wystub S; Brück P; Hoelzer D; Ottmann OG
Blood; 2007 Jul; 110(2):727-34. PubMed ID: 17405907
[TBL] [Abstract][Full Text] [Related]
37. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
Murai K; Akagi T; Shimosegawa K; Sugawara T; Ishizawa K; Ito S; Murai K; Motegi M; Yokoyama H; Noji H; Tajima K; Kimura J; Chou T; Ogawa K; Harigae H; Kubo K; Oba K; Sakamoto J; Ishida Y
Eur J Haematol; 2015 Dec; 95(6):558-65. PubMed ID: 25703064
[TBL] [Abstract][Full Text] [Related]
38. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
39. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Marin D; Ibrahim AR; Lucas C; Gerrard G; Wang L; Szydlo RM; Clark RE; Apperley JF; Milojkovic D; Bua M; Pavlu J; Paliompeis C; Reid A; Rezvani K; Goldman JM; Foroni L
J Clin Oncol; 2012 Jan; 30(3):232-8. PubMed ID: 22067393
[TBL] [Abstract][Full Text] [Related]
40. Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.
Ernst T; Hoffmann J; Erben P; Hehlmann R; Hochhaus A; Müller MC
Clin Chem Lab Med; 2008; 46(3):318-22. PubMed ID: 18303987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]